News for Ocuphire Pharma, Inc. (R3X1.F)

Published at

Mar 5, 2021 2:44 PM

by benzinga.com

neutral

neutral

Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol®

Efficacy Across Mydriatic Agents in Reversing Pharmacologically Induced Mydriasis Informed Phase 3 Registration MIRA-2 Study Design Topline Results for ...

R3X1.F R3X1.BE

Read more →
Published at

Jan 5, 2021 1:00 PM

by benzinga.com

mixed

mixed

Ocuphire Pharma Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances

Nyxol is in Late Stage Clinical Development for A New Ophthalmic Indication Top Line Data from LYNX-1 Expected 3Q2021 FARMINGTON HILLS, Mich., Jan. 05, 2021 ...

OCUP R3X1.F R3X1.BE

Read more →